86 results
424B5
CRNX
Crinetics Pharmaceuticals Inc
21 Jun 24
Prospectus supplement for primary offering
6:11pm
is owned by the users of its regulated subsidiaries. Access to the DTC system is also available to others, which we sometimes refer to as indirect
8-K
EX-1.1
CRNX
Crinetics Pharmaceuticals Inc
21 Jun 24
Other Events
5:24pm
in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific … and to the protection of such IT Systems and Sensitive Data from unauthorized use, access, misappropriation or modification. The Company and its subsidiaries have
S-3ASR
CRNX
Crinetics Pharmaceuticals Inc
21 Jun 24
Automatic shelf registration
4:45pm
Clearing Corporation, all of which are registered clearing agencies. DTCC is owned by the users of its regulated subsidiaries. Access to the DTC system
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
3 Jun 24
Regulation FD Disclosure
4:35pm
by an operator OR click the Call me™ link for instant telephone access to the event.
Call me™: https://emportal.ink/3K5zWA3
Webcast: https://viavid.webcasts.com
8-K
EX-99.1
nhy6lbfdsm f6n1
9 May 24
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results
4:12pm
DEFA14A
bbhi6 nul7
25 Apr 24
Additional proxy soliciting materials
4:48pm
8-K
EX-99.2
53dkeb5m2 94sjixbiz5
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
EX-99.1
vg2n3ukxerh
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
hn89x bgzrfienk5fti
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
EX-99.1
c1yq6
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
8-K
EX-10.1
oo0bg82
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
8-K
EX-10.2
mr4e7wt yn7hk
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
8-K
EX-99.1
kr16dtquhc86cuopw
28 Feb 24
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
sd5mrun hcfvbf9
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
qno5z8i6
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
EX-99.1
6fag1rvn42 125
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm